Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Offers Workshop On Non-Inferiority Studies Of Antibacterial Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

How to set the margins in non-inferiority studies of new antibacterial drugs is the hard question the workshop will tackle.

You may also be interested in...

Antibiotic Development: FDA Says New Guidances Will Help, But Industry Questions Statistical Focus

Industry is questioning the fundamental statistical underpinnings of FDA's approval pathways for antibiotics even as the agency prepares to roll out several guidances to help clarify them

FDA Shows When And How To Use, Or Not To Use, Non-Inferiority Trials

FDA’s eagerly awaited draft guidance on non-inferiority trials should facilitate greater, and easier, use of such trials. It even allows for the possibility of using a non-inferiority design for a single supportive pivotal trial, especially if the trial uses a definitive endpoint like an outcomes assessment.

CAP Drugs Must Meet Stricter Noninferiority Criteria Under Draft FDA Guidance

Biopharma firms developing drugs to treat community acquired pneumonia would be wise to follow the specifications FDA has set forth in a new 1draft guidance on the subject. The guidance specifies strict criteria for patient selection and confirmation of infection to support an evaluation based on noninferiority margins





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts